Pre-clinical cannabinoid analogs for new therapies
Official title: SimplePath IIB: Pre-clinical development of Cannabinoid analogs
Funded at Invizyne Technologies, INC. · NIH-11410047 · Data updated 2026-11-12
A biotech team is creating new, plant-inspired cannabinoid-like compounds in a cell-free system to see if they could help treat conditions like glaucoma, inflammatory bowel disease, Huntington’s disease, obesity, and chronic pain.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Invizyne Technologies, INC. NIH-funded |
| Lab location | 1 site (Monrovia, UNITED STATES) |
| Project start | July 1, 2026 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,034,289 |
| NIH project number | 2R44GM159516-05A1 |
| Project ID | NIH-11410047 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be patients with glaucoma, inflammatory bowel disease, Huntington’s disease, obesity, or chronic pain who could participate in future translational or clinical studies or benefit from future therapies arising from this research.
✕Less likely to help
Patients not affected by the target indications or those not eligible for future trials may not directly benefit.
What this research studies
This project aims to produce rare and new cannabinoid-like molecules using enzymatic, cell-free methods. The team will build a library of these compounds based on a resorcylic acid core and test how well they bind to CB1 and CB2 receptors. The goal is to identify analogs with favorable activity profiles that could lead to future treatments for CNS and inflammatory conditions. The work focuses on developing scalable production methods and rapid screening to map structure-activity relationships. If successful, these compounds could advance toward preclinical studies and potential clinical development.
Why it matters
Potential benefit: Potential new treatments for CNS and inflammatory conditions that may offer novel options where current therapies fall short.
How similar studies have gone: Previous work with cannabinoid analogs has shown receptor-binding activity and therapeutic potential, but this project also explores new-to-nature analogs and production methods.
Where this research is happening
-
Invizyne Technologies, INC.
Monrovia, United States Active
Researchers
- Principal investigator: Korman, Tyler P — Invizyne Technologies, INC.
- Study coordinator: Korman, Tyler P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.